Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 24c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q2 EPS of ($0.93), $0.24 better than the analyst estimate of ($1.17). Revenue for the quarter came in at $490 thousand versus the consensus estimate of $265 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens as Pivotal Trial Advances
• Kepler Cheuvreux Starts Jet2 plc (JET2:LN) (DRTGF) at Buy